오토인젝터 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Autoinjectors Market is presumed to reach the market size of nearly USD 7.16 Billion by 2032 from USD 1.78 Billion in 2023 with a CAGR of 16.74% under the study period 2024-2032.

An autoinjector is a medical device that enables the self-administration of a particular drug with less anxiety and stress. It is easy to use a spring-loaded syringe that is generally disposable. It can be used for intramuscular and subcutaneous injection, typically administered into the buttocks or the thigh. It comes in different shapes and sizes along with several features like adjustable injection depth, a drug inspection window, retractable needle, automated voice instruction, and color-coded spent indicator. This device is often used by military personnel for first aid to protect themselves from chemical warfare agents.

MARKET DYNAMICS

The widespread increase in self-administration of drug therapies among the global population will be the key driving force behind this market's growth. The aim to reduce the number of hospital visits and the expenses involved by health insurance agencies will further propel the autoinjectors' market among chronic patients. This market's main attractive segment is the growing trend to treat rheumatoid arthritis, multiple sclerosis, and diabetic patients using injectable self-administration. The various advantages of an autoinjector can save considerable time and money for the pharmaceutical and biopharmaceutical industries. The challenges faced by this market are related to the materials used for the manufacture of springs and other precision metal components used in an autoinjector

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Autoinjectors. The growth and trends of Autoinjectors industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Autoinjectors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Disposable
• Reusable

By Technology

• Handheld
• Wearable

By Route of Administration

• Subcutaneous
• Intramuscular

By Indication

• Multiple Sclerosis
• Rheumatoid Arthritis
• Diabetes
• Anaphylaxis
• Others (Oncology, Immunology etc.)

By End-user

• Homecare Settings
• Hospitals & Clinics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Autoinjectors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Autoinjectors market include Ypsomed Holding AG, Novartis AG, BD, Medmix Healthcare, Eli Lilly And Company, Sanofi, Mylan N.V., Amgen Inc., SHL Medical AG, Recipharm AB. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. AUTOINJECTORS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Indication
  • 3.7.5 Market Attractiveness Analysis By End-user
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Disposable Historic and Forecast Sales By Regions
• 5.4. Reusable Historic and Forecast Sales By Regions

6. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY TECHNOLOGY

• 6.1. Overview By Technology
• 6.2. Historical and Forecast Data Analysis By Technology
• 6.3. Handheld Historic and Forecast Sales By Regions
• 6.4. Wearable Historic and Forecast Sales By Regions

7. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data Analysis By Route of Administration
• 7.3. Subcutaneous Historic and Forecast Sales By Regions
• 7.4. Intramuscular Historic and Forecast Sales By Regions

8. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY INDICATION

• 8.1. Overview By Indication
• 8.2. Historical and Forecast Data Analysis By Indication
• 8.3. Multiple Sclerosis Historic and Forecast Sales By Regions
• 8.4. Rheumatoid Arthritis Historic and Forecast Sales By Regions
• 8.5. Diabetes Historic and Forecast Sales By Regions
• 8.6. Anaphylaxis Historic and Forecast Sales By Regions
• 8.7. Others (Oncology, Immunology etc.) Historic and Forecast Sales By Regions

9. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY END-USER

• 9.1. Overview By End-user
• 9.2. Historical and Forecast Data Analysis By End-user
• 9.3. Homecare Settings Historic and Forecast Sales By Regions
• 9.4. Hospitals & Clinics Historic and Forecast Sales By Regions

10. GLOBAL AUTOINJECTORS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE AUTOINJECTORS COMPANIES

• 11.1. Autoinjectors Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF AUTOINJECTORS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Ypsomed Holding AG
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Novartis AG
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. BD
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. Medmix Healthcare
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Eli Lilly And Company
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Sanofi
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Mylan N.V.
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Amgen Inc.
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. SHL Medical AG
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Recipharm AB
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies